Mar 23, 2023 8:00 am EDT Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
Feb 28, 2023 4:05 pm EST Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement
Feb 15, 2023 9:51 am EST Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
Jan 12, 2023 8:00 am EST Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops
Dec 20, 2022 8:00 am EST Eyenovia Announces Participation at the 2023 International Consumer Electronics Show
Dec 13, 2022 8:00 am EST Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
Dec 8, 2022 8:00 am EST Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
Nov 29, 2022 8:00 am EST Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Nov 10, 2022 4:05 pm EST Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update